Quick answer:
Dectin-1 is a sensor on certain immune cells that detects beta-glucans — natural compounds found in mushrooms and other fungi. This Dectin-1 beta-glucan relationship is well established in lab and animal studies (Brown & Gordon, 2001; Goodridge et al., 2011), but it needs confirmation in people.
This article walks through what’s known about Dectin-1 beta-glucans signaling, what isn’t, and how to read supplement claims with that in mind.
Written by the Superfood Science Editorial Team | Reviewed by Dr. Naafila Wiyono, M.D. | Last Updated: 09/29/2026
What is Dectin-1?
Dectin-1 is a receptor found on the surface of several types of white blood cells — macrophages, dendritic cells, and neutrophils. Its job is to detect beta-glucans, the sugar chains that make up much of a fungus’s cell wall. When it binds one, it can switch on the cell’s defensive activity. Its gene is called CLEC7A (Goodridge et al., 2011).
Think of your immune system as having two layers. The first layer — innate immunity — reacts quickly to broad patterns that signal “this looks like a microbe.” It does that with receptors that recognize shapes found on microbes but not on your own cells. Dectin-1 is one of those pattern-spotting receptors, and the pattern it spots is the beta-glucan chain in fungal cell walls (Goodridge et al., 2011).
Researchers identified it as a beta-glucan receptor on macrophages in 2001. At the time, another receptor, called complement receptor 3 (CR3), was already known to bind beta-glucans, but there was evidence that a second one existed. Dectin-1 turned out to be it (Brown & Gordon, 2001).
How does the Dectin-1 beta-glucans interaction work?
Dectin-1 recognizes shape. It binds beta-glucans built on a β-(1,3) backbone — glucose units linked in a particular way — and it needs a minimum length to bind at all. Branching, chain size, and the three-dimensional folding of the chain all affect how strongly immune cells respond (Han et al., 2020).
“Beta-glucan” isn’t one substance. It’s a family of glucose chains, and the way the glucose units are joined changes everything. Fungal beta-glucans — from mushrooms and from baker’s yeast — have a β-(1,3) backbone with β-(1,6) side branches (Vlassopoulou et al., 2021). Oat and barley beta-glucans are built differently, which is why they behave like a dietary fiber rather than something immune receptors recognize.
A 2020 review of the laboratory literature summarizes what Dectin-1 beta-glucan binding seems to require (Han et al., 2020):
• A long enough backbone. In lab testing, Dectin-1 “did not interact with linear β-(1,3)-D-glucan oligosaccharides shorter than seven glucose subunits.”
• Some branching. Beta-glucans with roughly one branch for every three to five backbone units were the most potent in the studies the review pooled.
• Size. Larger beta-glucans generally had a greater effect on immune cells than smaller ones.
Why does it matter whether a beta-glucan is particulate or soluble?
Because Dectin-1 can bind both forms but, in laboratory and mouse experiments, is only switched on by particles. A particle — like a fungal cell wall fragment — clusters many receptors together at once, which triggers the signal. A dissolved beta-glucan binds without clustering, so the signal stays off (Goodridge et al., 2011).
This is one of the most important findings in the field — it helps explain why a beta-glucan’s physical form matters as much as its source. The researchers showed that “despite its ability to bind both soluble and particulate β-glucan polymers, Dectin-1 signaling is only activated by particulate β-glucans” (Goodridge et al., 2011). They called the cluster that forms around a particle a “phagocytic synapse.”
Soluble beta-glucans aren’t simply inert, though. The 2020 review notes that they appear to work through a different route: “soluble glucans require a complement and CR3-dependent pathway activation” (Han et al., 2020).
|
|
Dectin-1 |
Complement receptor 3 (CR3) |
|
What it is |
A pattern-recognition receptor (C-type lectin), gene CLEC7A |
An integrin receptor also known as CD11b/CD18 |
|
Found on |
Macrophages, dendritic cells, neutrophils (Goodridge et al., 2011) |
Neutrophils and other white blood cells (Hong et al., 2004) |
|
Form of beta-glucan that activates it |
Particulate (Goodridge et al., 2011) |
Soluble, working together with the complement system (Han et al., 2020) |
|
Identified as a beta-glucan receptor |
2001 (Brown & Gordon, 2001) |
Before 2001 (Brown & Gordon, 2001) |
How do we know Dectin-1 matters in people?
The clearest human evidence comes from genetics, not supplements. In 2009, researchers described a family in which four women carried a mutation that disables Dectin-1. Their immune cells made fewer signaling proteins in response to beta-glucan, yet could still kill fungi normally. The women had recurrent fungal infections of mucous membranes or nails (Ferwerda et al., 2009).
The researchers described “a family in which four women who were affected by either recurrent vulvovaginal candidiasis or onychomycosis had the early-stop-codon mutation Tyr238X in the beta-glucan receptor dectin-1.” Their cells showed “defective production of cytokines” (cytokines are the chemical messages immune cells use to talk to each other), while their ability to kill fungi was preserved (Ferwerda et al., 2009).
Evidence grade: Human study (one family, genetic analysis plus laboratory tests of their cells).
What this tells us: Dectin-1 does real work in people, particularly at the body’s surfaces. What it does not tell us: that people without this rare mutation need anything extra, or that any supplement changes Dectin-1 beta-glucan signaling. A receptor mattering when it’s broken is a different question from whether it can be improved when it’s working.
Can a beta-glucan you swallow actually reach Dectin-1?
In mice, yes — at least for yeast beta-glucan particles, which gut immune cells carried into the spleen and bone marrow (Hong et al., 2004). In people, it hasn’t been shown. A 2014 human study found beta-glucan “barely detectable” in blood after a week of 1,000 mg daily, and no change in immune cell responses (Leentjens et al., 2014).
The mouse evidence. In a 2004 study, researchers fed mice yeast beta-glucan that had been tagged with a fluorescent label. Macrophages in the gut took it up and carried it to the spleen, lymph nodes, and bone marrow. In the bone marrow, the particles were broken down into smaller soluble fragments that then bound CR3 on neutrophils (Hong et al., 2004). This study was run in mouse cancer models, and it used yeast glucan, not a mushroom.
The human evidence. A 2014 study gave 10 healthy men 1,000 mg a day of an insoluble baker’s-yeast beta-glucan for 7 days; 5 more served as controls. The researchers then took blood samples, measured beta-glucan levels, and challenged the participants’ white blood cells with microbes in the lab (Leentjens et al., 2014). The results, in the authors’ words:
• “β-glucan was barely detectable in serum of volunteers at all time-points.”
• “Neither cytokine production nor microbicidal activity of leukocytes were affected by orally administered β-glucan.”
• “The present study does not support the use of oral β-glucan to enhance innate immune responses in humans.”
Evidence grade: Human study (small, open-label, randomized, healthy men only; the authors declared no competing interests).
Two honest caveats cut in both directions. The study was small and short, used yeast rather than mushroom beta-glucan, and measured blood cells rather than cells in the gut lining — where the mouse work suggests the action starts. But it is the most direct test in people that we could find, and it came back null. That gap between the lab/animal Dectin-1 beta-glucan mechanism and human confirmation is exactly what ongoing human research on oral beta-glucans, discussed below, is starting to address.
What is “trained immunity,” and does it apply to supplements?
“Trained immunity” is the finding that innate immune cells can respond more strongly to a second challenge after meeting certain microbial signals — a sort of short-term memory. In mice, this training by fungal beta-glucan required Dectin-1 (Quintin et al., 2012). It has not been shown to result from taking a beta-glucan supplement by mouth.
For a long time, immune “memory” was thought to belong only to T cells and B cells — the cells vaccines rely on. A 2012 study found that mice lacking T and B cells were still protected against a second Candida infection, and that the protection came from reprogrammed monocytes. The researchers reported that “the training required the beta-glucan receptor dectin-1” (Quintin et al., 2012).
What do human studies of oral beta-glucans actually show?
The human research is real and points in a useful direction. A 2021 systematic review of 34 randomized trials of fungal beta-glucans, in both healthy people and patients, concluded they are well tolerated and their effects show up mainly in immune measures (Vlassopoulou et al., 2021).
|
Study |
Who |
What they took |
What was found |
Evidence grade |
|
Vlassopoulou et al. (2021) |
34 RCTs; healthy adults and patient groups |
“Well-tolerated”; effects “manifested primarily through the potentiation of the immune system” |
Human studies (systematic review) |
|
|
Leentjens et al. (2014) |
15 healthy men |
1,000 mg/day insoluble baker’s-yeast beta-glucan, 7 days |
Barely detectable in blood; no change in cytokine production or microbe-killing by white blood cells |
Human study (small, open-label) |
|
Dai et al. (2015) |
52 healthy adults aged 21–41 |
5 g or 10 g of dried shiitake mushrooms a day (equivalent to 1–2 servings, or 3–6 oz of fresh mushrooms), 4 weeks |
Better-functioning gamma-delta T cells and lower levels of inflammatory proteins on blood tests |
Human study (whole food, not a supplement) |
A few things are worth noticing in that table:•
• Source matters. The only direct oral test of innate responses used yeast. The shiitake study used a whole food, so its effects can’t be pinned on beta-glucan alone (Dai et al., 2015).
• “Well tolerated” is a useful finding in itself. It’s the part of the review most people can act on (Vlassopoulou et al., 2021).
Who should talk to a doctor before taking a beta-glucan supplement?
Anyone with an autoimmune condition, anyone who has had an organ transplant, and anyone taking medicines that suppress the immune system should talk to their doctor first. The same applies during pregnancy or breastfeeding, and before surgery. A product sold for immune support is, by design, meant to interact with your immune system.
Frequently asked questions
What does Dectin-1 do? Dectin-1 is a receptor on macrophages, dendritic cells and neutrophils that recognizes beta-glucans in fungal cell walls. When a beta-glucan particle binds to it, the cell can switch on its defensive activity, such as releasing signaling proteins called cytokines (Goodridge et al., 2011).
Do mushroom beta-glucans bind to Dectin-1? Fungal beta-glucans, including those from mushrooms and yeast, share the β-(1,3) backbone with β-(1,6) branches that Dectin-1 recognizes in laboratory studies (Han et al., 2020; Vlassopoulou et al., 2021).
Is Dectin-1 the same as CR3? No. Both bind beta-glucans, but they are different receptors. In lab and mouse studies, Dectin-1 is activated by particulate beta-glucans, while soluble beta-glucans appear to act through complement receptor 3 (CR3) instead (Goodridge et al., 2011; Han et al., 2020).
Does oat beta-glucan work through Dectin-1? Oat and barley beta-glucans are built differently from fungal ones and are studied mainly as a soluble dietary fiber that works in the digestive tract.
Is a mushroom supplement a substitute for medical care? No. Supplements are not a replacement for medical care. If you have a health condition or take prescription medicines, talk to your doctor or pharmacist before starting one.
This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
Brown, G. D., & Gordon, S. (2001). Immune recognition: A new receptor for β-glucans. Nature, 413(6851), 36–37. https://doi.org/10.1038/35092620
Ferwerda, B., Ferwerda, G., Plantinga, T. S., Willment, J. A., van Spriel, A. B., Venselaar, H., Elbers, C. C., Johnson, M. D., Cambi, A., Huysamen, C., Jacobs, L., Jansen, T., Verheijen, K., Masthoff, L., Morré, S. A., Vriend, G., Williams, D. L., Perfect, J. R., Joosten, L. A. B., … Netea, M. G. (2009). Human dectin-1 deficiency and mucocutaneous fungal infections. The New England Journal of Medicine, 361(18), 1760–1767. https://doi.org/10.1056/NEJMoa0901053
Goodridge, H. S., Reyes, C. N., Becker, C. A., Katsumoto, T. R., Ma, J., Wolf, A. J., Bose, N., Chan, A. S. H., Magee, A. S., Danielson, M. E., Weiss, A., Vasilakos, J. P., & Underhill, D. M. (2011). Activation of the innate immune receptor Dectin-1 upon formation of a “phagocytic synapse.” Nature, 472(7344), 471–475. https://doi.org/10.1038/nature10071
Han, B., Baruah, K., Cox, E., Vanrompay, D., & Bossier, P. (2020). Structure-functional activity relationship of β-glucans from the perspective of immunomodulation: A mini-review. Frontiers in Immunology, 11, 658. https://doi.org/10.3389/fimmu.2020.00658
Hong, F., Yan, J., Baran, J. T., Allendorf, D. J., Hansen, R. D., Ostroff, G. R., Xing, P. X., Cheung, N.-K. V., & Ross, G. D. (2004). Mechanism by which orally administered β-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. The Journal of Immunology, 173(2), 797–806. https://doi.org/10.4049/jimmunol.173.2.797
Leentjens, J., Quintin, J., Gerretsen, J., Kox, M., Pickkers, P., & Netea, M. G. (2014). The effects of orally administered beta-glucan on innate immune responses in humans, a randomized open-label intervention pilot-study. PLOS ONE, 9(9), e108794. https://doi.org/10.1371/journal.pone.0108794
Quintin, J., Saeed, S., Martens, J. H. A., Giamarellos-Bourboulis, E. J., Ifrim, D. C., Logie, C., Jacobs, L., Jansen, T., Kullberg, B.-J., Wijmenga, C., Joosten, L. A. B., Xavier, R. J., van der Meer, J. W. M., Stunnenberg, H. G., & Netea, M. G. (2012). Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host & Microbe, 12(2), 223–232. https://doi.org/10.1016/j.chom.2012.06.006
Vlassopoulou, M., Yannakoulia, M., Pletsa, V., Zervakis, G. I., & Kyriacou, A. (2021). Effects of fungal beta-glucans on health – a systematic review of randomized controlled trials. Food & Function, 12(8), 3366–3380. https://doi.org/10.1039/D1FO00122A